Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093329 | 0.83 | NPSR1 (0.49) | NPSR1TSHREPHX2 | |
| SCHEMBL8584936 | 0.80 | NPSR1 (0.44) | NPSR1TSHREPHX2NAAA | |
| SCHEMBL2888682 | 0.80 | NPSR1 (0.44) | NPSR1TSHREPHX2ALDH1A1 | |
| SCHEMBL15037951 | 0.79 | NPSR1 (0.46) | NPSR1TSHREPHX2 | |
| SCHEMBL2986988 | 0.79 | HSD11B1 (0.33) | NPSR1TSHRHSD11B1ALDH1A1LMNA | |
| SCHEMBL18845034 | 0.79 | NPSR1 (0.46) | NPSR1TSHREPHX2 | |
| SCHEMBL1397825 | 0.79 | NPSR1 (0.47) | NPSR1TSHREPHX2ALDH1A1LMNA | |
| SCHEMBL13005842 | 0.78 | NPSR1 (0.49) | NPSR1TSHREPHX2ALDH1A1LMNA | |
| SCHEMBL23933250 | 0.77 | NPSR1 (0.46) | NPSR1TSHREPHX2ALDH1A1LMNA | |
| SCHEMBL231596 | 0.77 | NPSR1 (0.56) | NPSR1TSHREPHX2NAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533974-B2 | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | MICHIGAN DIAGNOSTICS, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150031889-A1 | ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES | GIRI BRIJ PAL (US) | 2015-01-29 | — | — | US | disclosed |
| US-8932881-B2 | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | GIRI BRIJ PAL (US) | 2015-01-13 | — | — | US | disclosed |
| US-8822233-B2 | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | GIRI BRIJ PAL (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140121362-A1 | NEW ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES | MICHIGAN DIAGNOSTICS, LLC (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140088297-A1 | NEW ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES | MICHIGAN DIAGNOSTICS, LLC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140073771-A1 | NEW ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES | MICHIGAN DIAGNOSTICS, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-8546150-B2 | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | Michigan Diagnostics, L.L.C. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| WO-2012059932-A1 | 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| EP-1453822-A4 | DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES | GIRI BRIJ P (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1453822-A2 | DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES | Giri, Brij P. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003054506-A2 | DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES | GIRI BRIJ PAL (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-0661271-B1 | AZEPINE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS SIGMA-RECEPTOR LIGANDS | ASAHI CHEMICAL IND (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5658923-A | USED IN TREATING DISEASES RELATED TO SIGMA-RECEPTOR, SUCH AS SCHIZOPHRENIA | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5650406-A | ANTISCHIZOPHRENIC AGENT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-07-22 | — | — | US | disclosed |
| US-5605795-A | Assays using chemiluminescent, enzymatically cleavable substituted 1,2-dioxetanes and kits therefor | TROPIX, INC. (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0757040-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1997-02-05 | — | — | EP | disclosed |
| EP-0661271-A1 | AZEPINE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-07-05 | — | — | EP | disclosed |
| US-5220005-A | Reactable with enzyme to release optically detectable energy | TROPIX, INC. (US) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088297-A1 | NEW ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES | DUOX1, XDH, MPO | NPSR1 3063/4885TSHR 1381/4885EPHX2 670/4885 |
| US-20140121362-A1 | NEW ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES | DUOX1, XDH, MPO | NPSR1 3063/4885TSHR 1381/4885EPHX2 670/4885 |
| US-20150031889-A1 | ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES | DUOX1, XDH, MPO | NPSR1 2918/4885TSHR 1113/4885EPHX2 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.